**Type of the Paper (Article, Review, Communication, etc.)**

**TITLE**

**Abstract**

**Background and Objectives:** Place the question addressed in a broad context and highlight the purpose of the study.

**Materials and Methods:** Describe briefly the main methods or treatments applied, including the study population description.

**Results:** Summarize the article’s main findings.

**Conclusions:** Indicate the main conclusions or interpretations. The abstract should be an objective representation of the article, it must not contain results which are not presented and substantiated in the main text and should not exaggerate the main conclusions.

**Keywords:** : keyword 1; keyword 2; keyword 3 (List three to ten pertinent keywords specific to the ar-ticle yet reasonably common within the subject discipline.)

**INTRODUCTION**

The introduction should briefly place the study in a broad context and highlight why it is important. It should define the purpose of the work and its significance. The current state of the research field should be carefully reviewed and key publications cited. Please highlight controversial and diverging hypotheses when necessary. Finally, briefly men-tion the main aim of the work and highlight the principal conclusions. As far as possible, please keep the introduction comprehensible to scientists outside your particular field of research.

If the name of the AUTHOR 3 is to be given in the text, a source should be added next to the name as superscript. The name of all authors should be stated in the references at the end of the text.

While writing the references, EndNote bibliography presentation program could be used and JAMA (or AMA) style in-text citation method should be used.

**MATERIALS AND METHODS**

The Materials and Methods should be described with sufficient details to allow oth-ers to replicate and build on the published results. Please note that the publication of your manuscript implicates that you must make all materials, data, computer code, and proto-cols associated with the publication available to readers. Please disclose at the submission stage any restrictions on the availability of materials or information. New methods and protocols should be described in detail while well-established methods can be briefly de-scribed and appropriately cited.

Research manuscripts reporting large datasets that are deposited in a publicly avail-able database should specify where the data have been deposited and provide the relevant accession numbers. If the accession numbers have not yet been obtained at the time of submission, please state that they will be provided during review. They must be provided prior to publication.

Interventionary studies involving animals or humans, and other studies that require ethical approval, must list the authority that provided approval and the corresponding ethical approval code.

In this section, where applicable, authors are required to disclose details of how gen-erative artificial intelligence (GenAI) has been used in this paper (e.g., to generate text, da-ta, or graphics, or to assist in study design, data collection, analysis, or interpretation). The use of GenAI for superficial text editing (e.g., grammar, spelling, punctuation, and format-ting) does not need to be declared.

**RESULTS**

The findings obtained from this section should be presented in a clear, concise and systematic manner. Findings should be structured in line with research questions or hypotheses, and the results of statistical analyses should be provided in detail. The main points to consider in the ‘Results’ section are as follows:

Objectivity:

Findings should be presented as they are, without interpretation. The meaning of the results, their interpretation, and comparison with the literature should be addressed in the ‘Discussion’ section.

Supporting with Numbers:

Findings should be presented in absolute values (n), percentages (%), mean ± standard deviation (or median [min–max], etc.). For example: ‘52% of participants were female (n=130) and the mean age was 34.7±9.3 years.’

Statistical Significance:

The results of statistical analyses should be clearly stated, including p-values (e.g., p<0.05), confidence intervals (e.g., 95% CI: 1.20–2.50), and, if necessary, measures such as odds ratio (OR) or risk ratio (RR).

Tables and Figures:

Tables and figures can be used to present data more clearly. These visuals should be explained with references in the text, but the text should not be repeated. Each table/figure should be understandable on its own and have descriptive titles.

Ordering and Subheadings:

Findings should be presented in an order consistent with the study's objectives. This makes it easier for the reader to follow the topic.

Negative and Unexpected Findings:

Findings that contradict the study hypothesis or are not meaningful should also be clearly stated for the sake of honesty.

All figures and tables should be cited in the main text as Figure 1, Table 1, etc.



**Figure 1.** This is a figure. Schemes follow the same formatting.

**Table 1.** This is a table. Tables should be placed in the main text near to the first time they are cited.

|  |  |  |
| --- | --- | --- |
| **Title 1** | **Title 2** | **Title 3** |
| entry 1 | data | data |
| entry 2 | data | data 1 |

1 Tables may have a footer.

The text continues here (Figure 2 and Table 2).

|  |  |
| --- | --- |
| C:\Users\martin\Downloads\testFigure.tif | C:\Users\martin\Downloads\testFigure.tif |
| (**a**) | (**b**) |

**Figure 2.** This is a figure. Schemes follow another format. If there are multiple panels, they should be listed as: (**a**) Description of what is contained in the first panel; (**b**) Description of what is contained in the second panel. Figures should be placed in the main text near to the first time they are cited.

**Table 2.** This is a table. Tables should be placed in the main text near to the first time they are cited.

|  |  |  |  |
| --- | --- | --- | --- |
| **Title 1** | **Title 2** | **Title 3** | **Title 4** |
| entry 1 \* | data | data | data |
| data | data | data |
| data | data | data |
| entry 2 | data | data | data |
| data | data | data |
| entry 3 | data | data | data |
| data | data | data |
| data | data | data |
| data | data | data |
| entry 4 | data | data | data |
| data | data | data |

\* Tables may have a footer.

**DISCUSSION**

Authors should discuss the results and how they can be interpreted from the per-spective of previous studies and of the working hypotheses. The findings and their impli-cations should be discussed in the broadest context possible. Future research directions may also be highlighted.

**CONCLUSION**

This section is mandatory and should contain the main conclusions regarding the research.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.ijtcmr.com/article/doi/s1, Figure S1: title; Table S1: title; Video S1: title.

**Author Contributions:** For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, X.X. and Y.Y.; methodology, X.X.; software, X.X.; validation, X.X., Y.Y. and Z.Z.; formal analysis, X.X.; investigation, X.X.; resources, X.X.; data curation, X.X.; writing—original draft preparation, X.X.; writing—review and editing, X.X.; visualization, X.X.; su-pervision, X.X.; project administration, X.X.; funding acquisition, Y.Y. All authors have read and agreed to the published version of the manuscript.” Please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

**Funding:** Please add: “This research received no external funding” or “This research was funded by NAME OF FUNDER, grant number XXX” and “The APC was funded by XXX”. Check careful-ly that the details given are accurate and use the standard spelling of funding agency names at https://search.crossref.org/funding. Any errors may affect your future funding.

**Institutional Review Board Statement:** In this section, you should add the Institutional Review Board Statement and approval number, if relevant to your study. You might choose to exclude this statement if the study did not require ethical approval. Please note that the Editorial Office might ask you for further information. Please add “The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Com-mittee) of NAME OF INSTITUTE (protocol code XXX and date of approval).” for studies involv-ing humans. OR “The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of NAME OF INSTITUTE (protocol code XXX and date of approval).” for studies involving animals. OR “Ethical review and approval were waived for this study due to REASON (please provide a detailed justification).” OR “Not applicable” for studies not involv-ing humans or animals.

**Informed Consent Statement:** Any research article describing a study involving humans should contain this statement. Please add “Informed consent was obtained from all subjects involved in the study.” OR “Patient consent was waived due to REASON (please provide a detailed justifica-tion).” OR “Not applicable.” for studies not involving humans. You might also choose to exclude this statement if the study did not involve humans. Written informed consent for publication must be obtained from participating patients who can be identified (including by the patients themselves). Please state “Written informed consent has been obtained from the patient(s) to publish this paper” if applicable.

**Data Availability Statement:** We encourage all authors of articles published in IJTCMR journals to share their research data. In this section, please provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or gener-ated during the study. Where no new data were created, or where data is unavailable due to privacy or ethical restrictions, a statement is still required. Suggested Data Availability State-ments are available in section “IJTCMR Research Data Policies” at https://www. dergipark.org.tr/en/pub/ijtcmr

**Acknowledgments:** In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments). Where GenAI has been used for purposes such as generating text, data, or graphics, or for study design, data collection, anal-ysis, or interpretation of data, please add “During the preparation of this manuscript/study, the author(s) used [tool name, version information] for the purposes of [description of use]. The authors have reviewed and edited the output and take full responsibility for the content of this publication.”

**Conflicts of Interest:** Declare conflicts of interest or state “The authors declare no conflicts of interest.” Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported re-search results. Any role of the funders in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results must be declared in this section. If there is no role, please state “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results”.

**REFERENCES** (source article names are representative) 1-6.

1. Gilman S, Newman SW. *Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology*. 10th ed. F.A. Davis; 2003.
2. Cohen M. Chronic and acute. In: Sapphire P, ed. *The Disenfranchised*. Baywood Publishing; 2013:109-122.
3. Hamilton GS, Naughton MT. Impact of obstructive sleep apnoea on diabetes and cardiovascular disease. *Med J Aust*. 2013;199(8):S27-30.
4. Johnson CL, Dohrmann SM, Kerckove VD, et al. National Health and Nutrition Examination Survey: National Youth Fitness Survey estimation procedures, 2012. *Vital Health Stat 2.* 2014;(168):1-25.
5. Thomas JL. Helpful or harmful? Potential effects of exercise on select inflammatory conditions. *Phys Sportsmed.* 2013;41(4):93-100. Accessed November 22, 2013. https://physsportsmed.org/psm.2013.11.2040
6. Surana NK, Kasper DL. Approach to the Patient with an Infectious Disease. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. *Harrison's Principles of Internal Medicine.* 20th ed. McGraw-Hill;2018:Chapter 115. Accessed October 15, 2020. https://accessmedicine.mhmedical.com/content.aspx?bookid=2129&sectionid=192019106